Imugene Limited (ASX:IMU)
0.0260
-0.0010 (-3.85%)
Apr 24, 2025, 1:28 PM AEST
Imugene Revenue
Imugene had revenue of 1.26M AUD in the half year ending December 31, 2024, a decrease of -73.86%. This brings the company's revenue in the last twelve months to -1.84M, down -112.24% year-over-year. In the fiscal year ending June 30, 2024, Imugene had annual revenue of 4.97M, down -57.80%.
Revenue (ttm)
-1.84M
Revenue Growth
-112.24%
P/S Ratio
-105.54
Revenue / Employee
-367.92K
Employees
5
Market Cap
194.14M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2024 | 4.97M | -6.81M | -57.80% |
Jun 30, 2023 | 11.78M | -1.19M | -9.19% |
Jun 30, 2022 | 12.97M | 5.74M | 79.35% |
Jun 30, 2021 | 7.23M | 3.10M | 74.94% |
Jun 30, 2020 | 4.13M | 6.56K | 0.16% |
Jun 30, 2019 | Pro | Pro | Pro |
Jun 30, 2018 | Pro | Pro | Pro |
Jun 30, 2017 | Pro | Pro | Pro |
Jun 30, 2016 | Pro | Pro | Pro |
Jun 30, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
CSL Limited | 24.61B |
Pro Medicus | 184.58M |
Cochlear | 2.31B |
Sonic Healthcare | 9.33B |
Telix Pharmaceuticals | 783.21M |
Ramsay Health Care | 17.12B |
Ansell | 3.00B |
Mesoblast | 9.16M |
Imugene News
- 7 months ago - Imugene Ltd Azer-cel Trial Update Transcript - GuruFocus
- 1 year ago - Bile Tract Cancer expansion study opens following clearance of Imugene's MAST trial high dose cohort - GlobeNewsWire
- 1 year ago - Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024 - GlobeNewsWire
- 1 year ago - Imugene Highlights Recent Achievements and Looks Ahead to Key Upcoming Immuno-oncology Catalysts - GlobeNewsWire
- 1 year ago - Imugene's CF33-hNIS (VAXINIA) & MAST Study Featured at ASCO GI Cancers Symposium - Accesswire
- 1 year ago - NeoImmuneTech and Imugene enter into strategic research collaboration to improve cancer treatments - PRNewsWire
- 3 years ago - City of Hope and Imugene Announce First Patient Dosed in Phase 1 Trial to Test Cancer-Killing Oncolytic Virus Against Solid Tumors - Business Wire
- 3 years ago - Imugene Announces Clinical Trial Collaboration with Merck & Co., Inc., Kenilworth, NJ., USA to Evaluate HER-Vaxx in Combination with Pembrolizumab for Treatment of Gastric Cancer - GlobeNewsWire